Dr. Knight et al., A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reducesischemic myocardial injury in vitro and in vivo, J PHARM EXP, 297(1), 2001, pp. 254-259
Citations number
36
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
The cardioprotective efficacy of zoniporide (CP-597,396), a novel, potent,
and selective inhibitor of the sodium-hydrogen exchanger isoform 1 (NHE-1),
was evaluated both in vitro and in vivo using rabbit models of myocardial
ischemia-reperfusion injury. In these models, myocardial injury was elicite
d with 30 min of regional ischemia and 120 min of reperfusion. Zoniporide e
licited a concentration-dependent reduction in infarct size (EC50 of 0.25 n
M) in the isolated heart (Langendorff) and reduced infarct size by 83% (50
nM). This compound was 2.5- to 20-fold more potent than either eniporide or
cariporide (EC50 of 0.69 and 5.11 nM, respectively), and reduced infarct s
ize to a greater extent than eniporide (58% reduction in infarct size). In
open-chest, anesthetized rabbits, zoniporide also elicited a dose-dependent
reduction in infarct size (ED50 of 0.45 mg/kg/h) and inhibited NHE-1-media
ted platelet swelling (maximum inhibition 93%). Furthermore, zoniporide did
not cause any in vivo hemodynamic (mean arterial pressure, heart rate, rat
e pressure product) changes. Zoniporide represents a novel class of potent
NHE-1 inhibitors with potential utility for providing clinical cardioprotec
tion.